Pramod Yadav, Jubilant Pharma Limited CEO

Ju­bi­lant Hol­lis­ter­Sti­er nets US gov­ern­ment con­tract to in­crease ac­tiv­i­ty at its grow­ing fa­cil­i­ty

A phar­ma­ceu­ti­cal con­tract man­u­fac­tur­er that has been grow­ing its pres­ence in the US has se­cured it­self a siz­able con­tract from the US gov­ern­ment.

Ju­bi­lant Hol­lis­ter­Sti­er, a sub­sidiary of Sin­ga­pore-based Ju­bi­lant Phar­ma Lim­it­ed, has en­tered in­to a co­op­er­a­tive agree­ment for $149.6 mil­lion with the Army Con­tract­ing Com­mand. The deal is al­so in co­or­di­na­tion with the Joint Pro­gram Ex­ec­u­tive Of­fice for Chem­i­cal, Bi­o­log­i­cal, Ra­di­o­log­i­cal and Nu­clear De­fense (JPEO-CBRND) on be­half of BAR­DA.

The ef­fort, which was fund­ed un­der the Amer­i­can Res­cue Plan, will en­able Ju­bi­lant Hol­lis­ter­Sti­er to dou­ble its in­jectable fill­ing pro­duc­tion ca­pac­i­ty at its Spokane, WA man­u­fac­tur­ing fa­cil­i­ty for a to­tal cost of $193 mil­lion. The project is slat­ed for com­ple­tion in 2025, ac­cord­ing to the com­pa­ny.

The com­pa­ny has a his­to­ry of sup­port­ing both HHS and the DOD with biode­fense and med­ical coun­ter­mea­sure pro­grams, in­clud­ing pro­duc­tion for na­tion­al pre­pared­ness ef­forts.

“Ju­bi­lant Hol­lis­ter­Sti­er LLC is com­mit­ted to mak­ing the US phar­ma­ceu­ti­cal sup­ply chain more re­silient with do­mes­tic man­u­fac­tur­ing fa­cil­i­ties and less re­liant on for­eign sup­pli­ers,” Ju­bi­lant Phar­ma CEO Pramod Ya­dav said in a state­ment.

In 2021, Ju­bi­lant sought to ex­pand its ster­ile in­jectable man­u­fac­tur­ing ca­pac­i­ty at its Spokane site to keep up with the de­mand sur­round­ing the Covid-19 vac­cine push. The ini­tial $92 mil­lion in­vest­ment is planned to in­crease man­u­fac­tur­ing ca­pac­i­ty by 50% with the in­clu­sion of 2,300-square-foot lyophiliz­ers and 50,000 square feet of build­ing space. The up­grades will al­low for 400 vials a minute to be filled.

Ear­li­er last year, the com­pa­ny al­so struck a deal with Eli Lil­ly for the man­u­fac­tur­ing of bam­lanivimab at the Spokane plant. How­ev­er, bam­lanivimab’s emer­gency use au­tho­riza­tion was re­voked by the FDA for the treat­ment of Covid-19.

In 2021, the com­pa­ny an­nounced that it had signed on with No­vavax to pro­vide fill-fin­ish ser­vices to its vac­cine can­di­date as well.

Vas Narasimhan (Photographer: Jason Alden/Bloomberg via Getty Images)

No­var­tis de­tails plans to axe 8,000 staffers as Narasimhan be­gins sec­ond phase of a glob­al re­org

We now know the number of jobs coming under the axe at Novartis, and it isn’t small.

The pharma giant is confirming a report from Swiss newspaper Tages-Anzeiger that it is chopping 8,000 jobs out of its 108,000 global staffers. A large segment will hit right at company headquarters in Basel, as CEO Vas Narasimhan axes some 1,400 of a little more than 11,000  jobs in Switzerland.

The first phase of the work is almost done, the company says in a statement to Endpoints News. Now it’s on to phase two. In the statement, Novartis says:

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,600+ biopharma pros reading Endpoints daily — and it's free.

How pre­pared is bio­phar­ma for the cy­ber dooms­day?

One of the largest cyberattacks in history happened on a Friday, Eric Perakslis distinctly remembers.

Perakslis, who was head of Takeda’s R&D Data Sciences Institute and visiting faculty at Harvard Medical School at the time, had spent that morning completing a review on cybersecurity for the British Medical Journal. Moments after he turned it in, he heard back from the editor: “Have you heard what’s going on right now?”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Sanofi to cut in­sulin prices for unin­sured from $99 to $35, match­ing the in­sulin cap com­ing through Con­gress

As the House-passed bill to cap the monthly price of insulin at $35 nationwide makes its way for a Senate vote soon, Sanofi announced Wednesday morning that beginning next month it will cut the monthly price of its insulins for uninsured Americans to $35, down from $99 previously.

The announcement from Sanofi, which allows the uninsured to buy one or multiple Sanofi insulins (Lantus, Insulin Glargine U-100, Toujeo, Admelog, and Apidra) at $35 for a 30-day supply effective July 1, follows House passage (232-193) of the monthly cap in March, with just 12 Republicans voting in favor of the measure.

Aurobindo Pharma co-founders P. V. Ram Prasad Reddy (L) and K. Nityananda Reddy

Au­robindo Phar­ma re­ceives warn­ing let­ter from In­di­a's SEC fol­low­ing more FDA ques­tion marks

Indian-based generics manufacturer Aurobindo Pharma has been in the crosshairs of the FDA for several years now, but the company is also attracting attention from regulators within the subcontinent.

According to the Indian business news site Business Standard, a warning letter was sent to the company from the Securities Exchange Board of India, or SEBI.

The letter is related to disclosures made by the company on an ongoing FDA audit of the company’s Unit-1 API facility in Hyderabad, India as well as observations made by the US regulator between 2019 and 2022.

Peter Marks (Jim Lo Scalzo/Pool via AP Images)

FDA's VRB­PAC votes in fa­vor of adapt­ing the Covid-19 vac­cine to the lat­est Omi­cron vari­ant

The FDA’s Vaccine and Related Biological Products Advisory Committee on Tuesday gave the thumbs up — by a vote of 19-2 — that the FDA should require an Omicron-related component in this next season’s booster dose for Covid-19, which both Pfizer/BioNTech and Moderna are hard at work on.

And while neither booster will likely be ready to go with adequate supplies for all American adults by the beginning of the next school year, the situation is still complex and fluid, with CBER Director Peter Marks telling the committee that it’ll take companies at least three months to ready their supplies for this expected next wave.

Bob Nelsen (Lyell)

As bear mar­ket con­tin­ues to beat down biotech, ARCH clos­es a $3B ear­ly-stage fund

One of the biggest names in biotech investing has a whole lot of new money to spend.

ARCH Venture Partners closed its 12th venture fund early Wednesday morning, the firm said, bringing in almost $3 billion to invest in early-stage biotechs. The move comes about a year and a half after ARCH announced its previous fund, for almost $2 billion back in January 2021.

In a statement, ARCH managing director and co-founder Bob Nelsen appeared to brush off concerns about the broader market troubles, alluding to the downturn that’s seen several biotechs downsize and the XBI fall back to almost pre-pandemic levels.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,600+ biopharma pros reading Endpoints daily — and it's free.

Lina Gugucheva, NewAmsterdam Pharma CBO

Phar­ma group bets up to $1B-plus on the PhI­II res­ur­rec­tion of a once dead-and-buried LDL drug

Close to 5 years after then-Amgen R&D chief Sean Harper tamped the last spade of dirt on the last broadly focused CETP cholesterol drug — burying their $300 million upfront and the few remaining hopes for the class with it — the therapy has been fully resurrected. And today, the NewAmsterdam Pharma crew that did the Lazarus treatment on obicetrapib is taking another big step on the comeback trail with a €1 billion-plus regional licensing deal, complete with close to $150 million in upfront cash.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,600+ biopharma pros reading Endpoints daily — and it's free.

(AP Photo/Gemunu Amarasinghe)

Some phar­ma com­pa­nies promise to cov­er abor­tion-re­lat­ed trav­el costs — while oth­ers won't go that far yet

As the US Department of Health and Human Services promises to support the millions of women who would now need to cross state lines to receive a legal abortion, a handful of pharma companies have said they will pick up employees’ travel expenses.

GSK, Sanofi, Johnson & Johnson, BeiGene, Alnylam and Gilead have all committed to covering abortion-related travel expenses just four days after the Supreme Court overturned Roe v. Wade and revoked women’s constitutional right to an abortion.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,600+ biopharma pros reading Endpoints daily — and it's free.

New Charles River Laboratories High Quality (HQ) Plasmid DNA Centre of Excellence at Bruntwood SciTech’s Alderley Park in Cheshire, United Kingdom. (Charles River)

Charles Riv­er Lab­o­ra­to­ries to start cell and gene ther­a­py man­u­fac­tur­ing at UK site in Sep­tem­ber

While Massachusetts-based Charles River Laboratories has been on an acquisition spree, they are not against planting their flag. The latest move by the company sees them crossing the pond to establish a manufacturing site in the UK.

The company on Tuesday opened its cell and gene therapy manufacturing center at Bruntwood SciTech’s Alderley Park in Cheshire, United Kingdom. The expansion follows Charles River’s acquisition of Cognate BioServices and Cobra Biologics in 2021 for $875 million. Cognate is a plasmid DNA, viral vector and cell therapy CDMO.